1 天
TipRanks on MSNAnalysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny StocksSome of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...
Sending an “open letter” to President Trump has been in vogue these days. Social activists, business moguls, media chieftains and political leaders all have penned a multitude of them since the ...
Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...
2 天
Zacks.com on MSNCRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate ...
Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...
As 2025 kicks off there’s lots of activity in the world of IP – particularly in the Biotech and Pharma sectors, writes Marc Wilkinson, Partner with J A Kemp. We at J A Kemp LLP have plenty to talk ...
The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.
Prosecutors say one of the men arrested Tuesday was working with a crew alleged to be behind the December burglary at the ...
This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...
USC has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to advance a new gene therapy for ...
In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果